The therapy, LentiGlobin, restored normal blood function in 35 sickle cell patients who had the one-time procedure, according to clinical trial findings published in the New England Journal of Medicine. “The patients are all now producing stable amounts of normal red blood cells containing healthy hemoglobin,” said lead researcher Dr. Julie Kanter, director of the...